AuthorisedHuman Pharmacology (Phase I)- OtherHistologically confirmed locally advanced or metastatic solid tumor
(Strata A, B, D):
Specification for Stratum C: Only patients with NSCLC adenocarcinomas,
(squamous or adenosquamous not permitted) who are scheduled to
receive platin + pembrolizumab + pemetrexed standard treatment (only
for Stratum C)
Specification for Stratum E: Including only metastatic or irresectable
locally advanced urothelial carcinomas (only for Stratum E)
„INSIGHT“
An explorative, open-labeled, phase I trial to evaluate feasibility and safety of eftilagimod alpha (IMP321, a LAG-3Ig fusion protein acting as LAG-3 agonist) in combination with immunotherapeutic, targeted or chemotherapeutic agents or when administered via new routes of application in advanced stage solid tumors
EU CTIS ID: 2024-516026-56-00
What this study is testing
Human Pharmacology (Phase I)- Other
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
BridgeMD is an information and trial-matching tool - not medical advice, and not the
study sponsor. Details come from EU CTIS; the study team decides eligibility.
BridgeMD